VERTEX PHARMACEUTICALS INC (1VRTX.MI) Stock Overview
BIT:1VRTX - US92532F1003 - Common Stock
1VRTX.MI Key Statistics, Chart & Performance
The current stock price of 1VRTX.MI is 336.75 EUR. In the past month the price decreased by -11.7%.
1VRTX.MI Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 4AB.DE | ABBVIE INC | 19.56 | 315.15B | ||
| AMG.DE | AMGEN INC | 13.16 | 133.16B | ||
| GIS.DE | GILEAD SCIENCES INC | 14.72 | 121.84B | ||
| VX1.DE | VERTEX PHARMACEUTICALS INC | 22.96 | 85.90B | ||
| ARGX.BR | ARGENX SE | 79.3 | 36.11B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 21.84B | ||
| 1BIIB.MI | BIOGEN INC | 8.7 | 17.58B | ||
| IDP.DE | BIOGEN INC | 8.54 | 17.27B | ||
| 1EXEL.MI | EXELIXIS INC | 17.31 | 8.97B | ||
| 1MRNA.MI | MODERNA INC | N/A | 8.62B | ||
| 0QF.DE | MODERNA INC | N/A | 8.60B | ||
| ABVX.PA | ABIVAX SA | N/A | 4.94B |
Related stock screener links
About 1VRTX.MI
Company Profile
Vertex Pharmaceuticals, Inc. is a global biotechnology company, which engages in the business of discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases. The company is headquartered in Boston, Massachusetts and currently employs 6,100 full-time employees. The company has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
Company Info
VERTEX PHARMACEUTICALS INC
50 Northern Avenue
Boston MASSACHUSETTS US
Employees: 6100
Phone: 16173416393
VERTEX PHARMACEUTICALS INC / 1VRTX.MI FAQ
What is the stock price of VERTEX PHARMACEUTICALS INC today?
The current stock price of 1VRTX.MI is 336.75 EUR. The price decreased by -12.44% in the last trading session.
What is the ticker symbol for VERTEX PHARMACEUTICALS INC stock?
The exchange symbol of VERTEX PHARMACEUTICALS INC is 1VRTX and it is listed on the Euronext Milan exchange.
On which exchange is 1VRTX.MI stock listed?
1VRTX.MI stock is listed on the Euronext Milan exchange.
What is the price forecast or stock price prediction for VERTEX PHARMACEUTICALS INC stock?
40 analysts have analysed 1VRTX.MI and the average price target is 438.94 EUR. This implies a price increase of 30.35% is expected in the next year compared to the current price of 336.75. Check the VERTEX PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is VERTEX PHARMACEUTICALS INC worth?
VERTEX PHARMACEUTICALS INC (1VRTX.MI) has a market capitalization of 86.48B EUR. This makes 1VRTX.MI a Large Cap stock.
How many employees does VERTEX PHARMACEUTICALS INC have?
VERTEX PHARMACEUTICALS INC (1VRTX.MI) currently has 6100 employees.
Is VERTEX PHARMACEUTICALS INC (1VRTX.MI) expected to grow?
The Revenue of VERTEX PHARMACEUTICALS INC (1VRTX.MI) is expected to grow by 9.56% in the next year. Check the estimates tab for more information on the 1VRTX.MI EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy VERTEX PHARMACEUTICALS INC (1VRTX.MI) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of 1VRTX.MI, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of 1VRTX.MI, evaluating the profitability, health, valuation and growth aspects
- VERTEX PHARMACEUTICALS INC (1VRTX.MI) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- VERTEX PHARMACEUTICALS INC (1VRTX.MI) Sales and EPS estimates to see what analysts future expectations are.
- VERTEX PHARMACEUTICALS INC (1VRTX.MI) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- VERTEX PHARMACEUTICALS INC (1VRTX.MI) Insider and Institutional Ownership to learn about the owners and their transactions.
- VERTEX PHARMACEUTICALS INC (1VRTX.MI) Stock Chart to make your own analysis
- VERTEX PHARMACEUTICALS INC (1VRTX.MI) Latest news and press-releases to stay up to date.
Does VERTEX PHARMACEUTICALS INC (1VRTX.MI) stock pay dividends?
1VRTX.MI does not pay a dividend.
When does VERTEX PHARMACEUTICALS INC (1VRTX.MI) report earnings?
VERTEX PHARMACEUTICALS INC (1VRTX.MI) will report earnings on 2025-08-04, after the market close.
What is the Price/Earnings (PE) ratio of VERTEX PHARMACEUTICALS INC (1VRTX.MI)?
VERTEX PHARMACEUTICALS INC (1VRTX.MI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.35).
1VRTX.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1VRTX.MI.
1VRTX.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to 1VRTX.MI. 1VRTX.MI has an excellent financial health rating, but there are some minor concerns on its profitability.
1VRTX.MI Financial Highlights
Over the last trailing twelve months 1VRTX.MI reported a non-GAAP Earnings per Share(EPS) of -0.35. The EPS decreased by -102.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -4.32% | ||
| ROE | -5.99% | ||
| Debt/Equity | 0.01 |
1VRTX.MI Forecast & Estimates
40 analysts have analysed 1VRTX.MI and the average price target is 438.94 EUR. This implies a price increase of 30.35% is expected in the next year compared to the current price of 336.75.
For the next year, analysts expect an EPS growth of 6211.74% and a revenue growth 9.56% for 1VRTX.MI